INOVIO PHARMACEUTICAL INC (GBMB.DU)
Chart Events
Performance Outlook
| Previous Close | 1.5914 |
| Open | 1.5928 |
| Bid | 1.7552 x N/A |
| Ask | 1.7928 x N/A |
| Day's Range | 1.5836 - 1.7646 |
| 52 Week Range | 1.2960 - 3.5925 |
| Volume | |
| Avg. Volume | 8 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Inovio Pharma Releases Favorable Data From Booster DNA Vaccine Candidate For Ebola
Inovio Pharmaceuticals Inc (NASDAQ: INO) announced results from a Phase 1b trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo. Ervebo is an FDA-approved vaccine to prevent ebola in individuals 18 years and older. In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants. Dr. Laurent Humeau, PhD, INOVIO's Chief Scientific Officer, said, "We are
- American City Business Journals
Inovio Pharmaceuticals enacts its second round of layoffs in just over six months
The company also announced court approval of a previously disclosed $44 million settlement to resolve a class-action shareholder lawsuit.
- Benzinga
INOVIO Announces Further Reorganization, Continues Focus on Promising DNA Candidates
INOVIO Pharmaceuticals (NASDAQ: INO) announced a strategic reorganization expected to provide annual savings of approximately $4.3 million and includes an 11% reduction of full-time employees following the previously announced discontinuation of clinical development programs in late 2022. In October, the company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. These and other strategic measures redirect resources to advance key programs,
